Shares of 4D Pharma PLC (LON: DDDD) today surged 9.67% after the company announced the appointment of an independent non-executive director Katrin Rupalla, PhD, which many analysts cheered as a strategic move.
Dr Rupalla has over 20 years experience in the pharmaceuticals industry having worked in both clinical and regulatory roles within the neuroscience and oncology specialities.
Her prior experience includes senior roles at Merck & Co., Celgene, Roche and Bristol-Myers Squibb (BMS).
Dr Rupalla has led regional and global teams tasked with getting regulatory approvals for multiple new therapies including Opdivo, Rituxan, Yervoy, Xeloda, Revlimid, Avastin, and Vidaza, among others.
She will play a critical role in 4D pharma’s immediate and long-term clinical strategy across its Live Biotherapeutic development pipeline, including the application of the Rx platform and other pre-clinical projects.
Duncan Peyton, 4D’s CEO, commented: “We are delighted to be able to attract someone of Katrin’s calibre to our Board of Directors. Her vast experience guiding novel therapies through the clinic will be invaluable as we progress our pipeline of novel Live Biotherapeutics into and through the clinic. With her background so well aligned with 4D’s core focus areas of oncology and CNS, Katrin’s experience and network across Europe, the US and China will support 4D’s growth as we continue to expand our global profile.”
4D Pharma share price
4D Pharma shares today rallied 9.67% to trade at 170p having ended Tuesday’s session trading at 155p.